Albireo Provides First Quarter 2018 Business Update

5/17/18

BOSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided corporate highlights for the beginning of 2018.

“The beginning of 2018 has been a landmark period for Albireo,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We achieved a major milestone with enrollment of the first patient in PEDFIC-1, our Phase 3 clinical trial with A4250, an ileal bile acid transporter (IBAT) inhibitor, in progressive familial intrahepatic cholestasis (PFIC). In January, we announced that our licensee received regulatory approval in Japan for the world’s first approved IBAT inhibitor, elobixibat, for the treatment of chronic constipation. This is strong validation of our scientific platform, and it triggered over $55 million in payments to Albireo. In addition, we raised over $94 million in net proceeds from equity financings.”

Recent Highlights

A4250

  • Enrolled first patient in the PEDFIC-1 study, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of A4250 in patients with PFIC (subtype 1 or 2). The Phase 3 program includes a single randomized, double-blind, placebo-controlled clinical trial designed to evaluate A4250 in approximately 60 patients, ages 6 months to 18 years, with elevated serum bile acid (sBA) levels and pruritus, and an open-label extension study to assess long-term safety and durability of response. Initiation of the study followed extensive dialogue with regulatory authorities in the US and EU. Additional trial sites are being activated around the world to generate data in support of potential drug approval applications for A4250 in the US and EU. A4250 has received orphan drug designation for PFIC in the US and EU, and has been granted access to the EMA’s PRIority MEdicines (PRIME) program for the treatment of PFIC.
  • Presented positive data on a pruritus pharmacodynamic marker measured in the completed Phase 2 clinical trial of A4250 in children with cholestatic liver disease and pruritus at the European Association for the Study of the Liver (EASL) The International Liver Congress™ in April 2018 in a poster, titled “Correlation of autotaxin levels, serum bile acids, and pruritus in a multiple-dose, open-label, multinational study of the ileal bile acid transport inhibitor A4250.”

Elobixibat

  • Elobixibat became the first IBAT inhibitor approved anywhere in the world. Japan’s Ministry of Health, Labor and Welfare approved a new drug application for elobixibat for the treatment of chronic constipation in Japan in January 2018. This triggered a milestone payment from EA Pharma Co., Ltd. of over $10 million.
  • Albireo subsidiary Elobix AB entered into an agreement to monetize its royalty rights under its license agreement with EA Pharma for elobixibat in the treatment of chronic constipation in Japan with HealthCare Royalty Partners in January 2018. Elobix received a $45 million payment from HealthCare Royalty Partners, with the potential for an additional $15 million.

Corporate

  • Raised $94.1 million in net proceeds from equity financings.
  • Presented at multiple investor conferences, including the Cowen and Company Health Care Conference, Roth Healthcare Conference, Needham & Company Healthcare Conference and the H.C. Wainwright Global Life Sciences Conference.

About Albireo 

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.